Strategic partnerships RxCelerate has a track record of forming collaborations (Constructive Bio integration in 2025, PlaqueTec collaboration in 2024) and operates with sister companies (RxBiologics, The Cambridge Partnership). Leverage these alliance dynamics to position joint offerings or co-developed solutions for biologics and complex targets.

Rapid hit discovery Recent launch of RxPlorer in 2026 highlights a focus on accelerating small molecule hit finding and screening against undruggable targets. Position services around speed-to-hit, target expansion for challenging chemistries, and integration with existing discovery pipelines.

Broad service integration One-stop shop capabilities spanning in silico modeling, medicinal chemistry, in vitro, preclinical, and project management. This breadth enables cross-sell to clients seeking turnkey drug development programs and reduces vendor management overhead.

Biologics focus elevating value RxBiologics and advisory board formation signal a growing emphasis on antibody discovery and next-gen biologics. Target biopharma clients pursuing biologics programs, and offer value propositions around engineered proteins and ncAA-enabled approaches.

Geographic and market reach Active presence across Europe and the USA with a mid-size team (51-200 employees) and mid-market revenue. Market aggressively in cross-Atlantic collaborations, biopharma sponsor opportunities, and funded research programs to expand client base.